Louise Chen
Stock Analyst at Scotiabank
(2.68)
# 790
Out of 5,182 analysts
293
Total ratings
46.98%
Success rate
2.94%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $30.82 | +29.79% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $238.46 | +11.13% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $58.62 | +2.35% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $121.42 | -1.17% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $748.87 | +2.82% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $21.18 | +277.71% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $4.04 | +122.77% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $32.82 | -57.34% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.80 | +566.67% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $23.76 | +131.48% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $68.69 | -19.93% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $4.47 | +235.57% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $127.12 | -60.67% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $6.18 | +142.72% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $36.37 | -53.26% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $18.68 | +167.67% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $8.05 | +272.67% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $20.68 | +165.96% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.67 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $37.52 | +326.44% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $60.88 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $207.94 | +15.42% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.92 | +67.16% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.47 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.21 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $939.47 | -5.80% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.27 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $24.50 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.00 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.94 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.16 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.48 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.08 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.00 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.49 | +1,762.46% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.82 | +77.30% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.24 | +228.08% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $24.21 | +106.53% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.07 | +141.55% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.61 | +1,375.41% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.37 | +457,316,973.17% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $211.60 | +21.93% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $0.85 | +5,761.66% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.16 | +1,624.14% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $5.17 | +770.41% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $30.82
Upside: +29.79%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $238.46
Upside: +11.13%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $58.62
Upside: +2.35%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $121.42
Upside: -1.17%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $748.87
Upside: +2.82%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $21.18
Upside: +277.71%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $4.04
Upside: +122.77%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $32.82
Upside: -57.34%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.80
Upside: +566.67%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $23.76
Upside: +131.48%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $68.69
Upside: -19.93%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.47
Upside: +235.57%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $127.12
Upside: -60.67%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $6.18
Upside: +142.72%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $36.37
Upside: -53.26%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $18.68
Upside: +167.67%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $8.05
Upside: +272.67%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.68
Upside: +165.96%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.67
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $37.52
Upside: +326.44%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $60.88
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $207.94
Upside: +15.42%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.92
Upside: +67.16%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.47
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.21
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $939.47
Upside: -5.80%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.27
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $24.50
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.00
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.94
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.16
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.48
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.08
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.00
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.49
Upside: +1,762.46%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.82
Upside: +77.30%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.24
Upside: +228.08%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $24.21
Upside: +106.53%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.07
Upside: +141.55%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.61
Upside: +1,375.41%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.37
Upside: +457,316,973.17%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $211.60
Upside: +21.93%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $0.85
Upside: +5,761.66%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.16
Upside: +1,624.14%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $5.17
Upside: +770.41%